Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Inclusion Criteria: * Primary or de Novo MDS * Low to Intermediate-1 IPSS risk of MDS * ECOG performance score of 0 or 1 * Documentation of significant anemia with or without additional cytopenia * Adequate kidney and liver function * Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry Exclusion Criteria: * Deletion of the 5q chromosome \[del(5q) MDS\] * Prior allogenic bone marrow transplant for MDS * Known sensitivity to ezatiostat (injection or oral tablets) * Prior treatment with hypomethylating agent (HMA) (e.g., azacitadine, decitabine) * History of MDS IPSS risk score of greater than 1.0 * Pregnant or lactating women * Any severe concurrent disease, infection or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry * Oral steroids greater than 10 mg per day. Exceptions: those prescribed for other conditions (such as new adrenal failure, asthma, arthritis) or brief sterioid use (such as tapered dosing for an acute non-MDS condition) * History of hepatitis B or C, or HIV